Neutrophil to Lymphocyte Ratio after Treatment Completion as a Potential Predictor of Survival in Patients with Triple-Negative Breast Cancer

김광민; 최향숙; 노하니; 조인정; 임승택; 이종인; 한애리

doi:10.4048/jbc.2021.24.e43

추천

검색

자료유형: 학술저널

저자정보: 김광민 (Department of Surgery Yonsei University Wonju College of Medicine Wonju Korea) 최향숙 (Department of Surgery Yonsei University Wonju College of Medicine Wonju Korea) 노하니 (Department of Surgery Yonsei University Wonju College of Medicine Wonju Korea) 조인정 (Department of Surgery Yonsei University Wonju College of Medicine Wonju Korea) 임승택 (Department of Oncology Yonsei University Wonju College of Medicine Wonju Korea) 이종인 (Department of Oncology Yonsei University Wonju College of Medicine Wonju Korea) 한애리 (연세대학교)

저널정보: 한국유방암학회 Journal of Breast Cancer Journal of Breast Cancer Vol.24 No.5

발행연도: 2021.10

수록면: 443 - 454 (12page)

DOI: 10.4048/jbc.2021.24.e43

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose Triple-negative breast cancer (TNBC) has been associated with worse prognosis, and biomarkers are needed to identify high-risk patients who may benefit from clinical trials or escalated treatment after completion of standard treatment. We aimed to assess whether the post-treatment neutrophil-to-lymphocyte ratio (NLR) can reflect patient prognosis and determine the follow-up period that can provide the most feasible data. Methods In this retrospective analysis involving patients with TNBC, clinicopathological data, including those on peripheral complete blood cell count, were collected. The prognostic powers of serial NLRs obtained at baseline and after treatment completion were compared. Kaplan-Meier curves were generated to compare the overall survival (OS) and distant disease-free survival (DDFS). Results In total, 210 patients were enrolled. Forty-three (20.5%) events were detected. Two-thirds of the events (29/43) were related to breast cancer. Most recurrent breast cancer-related diseases (27/29) were detected within 5 years of the initial diagnosis. In contrast, half of the events due to secondary malignancies or non-breast-related diseases (7/14) occurred 5 years after the initial diagnosis. Comparison of the prognostic performance of NLRs at baseline and at 6, 12, and 24 months after treatment completion revealed the strongest prognostic performance at 6 months after treatment completion (area under the curve = 0.745). The high NLR group (NLR >2.47) showed worse OS (p = 0.006) and DDFS (p < 0.001) than low NLR group. Conclusion Elevated post-treatment NLR was significantly associated with worse survival in patients with TNBC. We believe that it can be a useful surrogate marker for identifying high-risk patients with TNBC.

#Lymphocytes #Neutrophils #Survival #Triple negative breast neoplasms

참고문헌 (29)

참고문헌 신청

Schmid P / 2020 / Pembrolizumab for early triple-negative breast cancer / N Engl J Med 382:810~821

Mittendorf EA / 2020 / Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial / Lancet 396:1090~1100

Davies C / 2013 / Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial / Lancet 381:805~816

Cuzick J / 2010 / Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial / Lancet Oncol 11:1135~1141

Joensuu H / 2018 / Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial / JAMA Oncol 4:1199~1206

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!